Affymax is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases. Affymax’s objective is to discover, develop and commercialize novel therapeutics addressing large unmet medical needs. In August 2001, a collaboration of several venture firms created Affymax as an independent company—a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs.

Hematide™, our first product candidate to enter the clinic, is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for the treatment of anemia. Hematide is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure.

Anemia associated with chronic renal failure is estimated to be an almost $7 billion worldwide market.